<DOC>
	<DOCNO>NCT00805168</DOCNO>
	<brief_summary>To demonstrate adjunctive therapy intravenous ( IV ) antibiotic , BAY 41-6551 400 mg ( amikacin free base ) administer aerosol Pulmonary Drug Delivery System ( PDDS ) Clinical every 12 hour safe effective placebo ( aerosolize normal saline ) administer aerosol PDDS Clinical every 12 hour , intubate mechanically-ventilated patient Gram-negative Pneumonia . The secondary endpoint objective evaluate superiority aerosolize BAY 41-6551 versus aerosolize placebo pneumonia-related mortality , Early Clinical Response Day 10 , day ventilation , day intensive care unit ( ICU ) .</brief_summary>
	<brief_title>Inhaled Amikacin Solution ( BAY 41-6551 ) Adjunctive Therapy Treatment Gram-Negative Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<criteria>Males nonpregnant , nonlactating female , 18 year age older Intubated mechanicallyventilated Diagnosis pneumonia define presence new progressive infiltrate ( ) chest radiograph Presence Gramnegative organism ( ) either Gram stain culture respiratory secretion , suspect Gramnegative pathogen Impaired oxygenation Clinical Pulmonary Infection Score ( CPIS ) least 6 Presence least two risk factor multidrug resistant organism History hypersensitivity amikacin aminoglycosides Has receive antibiotic therapy Gramnegative pneumonia great 48 hour time randomization Known suspect bacteremia secondary Staphylococcus aureus A positive urine and/or serum betahuman Chorionic Gonadotropin pregnancy test Patients serum creatinine &gt; 2 mg/dL ( 177 Âµmol/L ) [ Exception : Patients serum creatinine &gt; 2 mg/dL ( 177 umol/L ) treat continuous renal replacement therapy ( Continuous VenoVenous Hemodialysis CVVHemoDiafiltration ) daily hemodialysis receive aerosol study drug treatment ] Has mechanical ventilation &gt; 28 day Is participate participated investigational interventional study within last 28 day prior study treatment The risk rapidly fatal illness death within 72 hr , concomitant condition relate ventilatorassociated pneumonia , opinion investigator , preclude completion study evaluation course therapy Has Acute Physiology Chronic Health Evaluation ( APACHE ) II score &lt; 10 Patients receive venovenous extracorporeal circulation membrane oxygenation ( VV ECMO )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gram-negative Pneumonia</keyword>
	<keyword>Pneumonia</keyword>
	<keyword>Intubation</keyword>
	<keyword>Mechanical ventilation</keyword>
	<keyword>Amikacin</keyword>
</DOC>